Last reviewed · How we verify
NCT04808791
iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 2 trial testing Irinotecan in Gastroesophageal Junction Adenocarcinoma in 7 participants. Completed in 21 July 2023.
7 July 2023
Quick facts
| Lead sponsor | AHS Cancer Control Alberta |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 7 |
| Start date | 27 October 2021 |
| Primary completion | 7 July 2023 |
| Estimated completion | 21 July 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Irinotecan (irinotecan) — full drug profile →
- Oxaliplatin (Oxaliplatin) — full drug profile →
- TAS 102 (Trifluridine/Tipiracil) — full drug profile →
Conditions studied
- Gastroesophageal Junction Adenocarcinoma — all drugs for Gastroesophageal Junction Adenocarcinoma →
- Advanced Gastric Carcinoma — all drugs for Advanced Gastric Carcinoma →
Sponsor
AHS Cancer Control Alberta — full company profile →
Who can join
18 and older, any sex, with Gastroesophageal Junction Adenocarcinoma or Advanced Gastric Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the safety and feasibility of Irinotecan, Trifluridine/Tipiracil (TAS-102) and Oxaliplatin (iTTo) for treatment naïve advanced gastric or gastroesophageal junction adenocarcinoma.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
Shitara K, Falcone A, Fakih MG, George B, et al · · 2024 · cited 3× · PMID 38366864 · DOI 10.1093/oncolo/oyae007 -
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
Shitara K, George B, Taieb J, Sundar R, et al · · 2023 · cited 2× · PMID 37213030 · DOI 10.1007/s00432-023-04813-z
Verify or expand the search:
- PubMed search for NCT04808791
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Irinotecan
Trials testing the same drug.
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
- NCT07487896 — A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esopha · Phase 3 · not yet recruiting
- NCT07474727 — A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07381764 — ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected M · Phase 2 · not yet recruiting
Other recruiting trials for Gastroesophageal Junction Adenocarcinoma
Currently open trials in the same condition.
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07311408 — SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure · Phase 2 · recruiting
- NCT07182565 — Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcin · Phase 1, PHASE2 · recruiting
- NCT07179484 — To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric · recruiting
- NCT07072351 — Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Ade · Phase 1, PHASE2 · recruiting
Other AHS Cancer Control Alberta trials
Trials by the same sponsor.
- NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
- NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
- NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
- NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
- NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04808791 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AHS Cancer Control Alberta
- Last refreshed: 14 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04808791.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing